TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

OVERVIEW OF ACTIVITY
Until recently, treatments for advanced melanoma had been relatively limited in their overall effectiveness. However, unprecedented strides have been made in defining molecular mechanisms of critical importance to melanoma development, progression and metastasis, and these have in turn led to a number of therapeutic advances that have completely redefined treatment algorithms and outcomes for patients. In addition, similar to the drug development paradigm employed by investigators working in other solid tumors, melanoma researchers have attempted to leverage the aforementioned advances for patients with more localized presentations of the disease. This relatively sudden availability of a host of new therapies and a number of other emerging strategies that may soon join them has created a multitude of uncertainties and important clinical questions.

These video proceedings from a CME symposium held during the 2019 ASCO Annual Meeting feature discussions with leading researchers with an expertise in melanoma regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and potential benefits of existing and recently approved systemic approaches.
• Consider age, performance status and other disease-related factors to guide the selection of first- and later-line therapy for patients with metastatic BRAF wild-type melanoma.
• Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with a BRAF tumor mutation.
• Recognize the recent FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with a BRAF tumor mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
• Identify adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize or manage side effects.
• Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy) for patients with advanced melanoma, and counsel appropriate patients about availability and participation.
• Recall new data with other investigational agents and strategies demonstrating promising activity in melanoma, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Professor Georgina Long, BSc, PhD, MBBS
Co-Medical Director of Melanoma Institute Australia
Chair of Melanoma Medical Oncology and Translational Research
Melanoma Institute Australia and Royal North Shore Hospital
The University of Sydney
Sydney, Australia

Advisory Committee: Aduro Biotech, Agena Bioscience Inc, Amgen Inc, Bristol-Myers Squibb Company, Merck, Novartis, OncoSec Medical, Pierre Fabre, Roche Laboratories Inc.

Jason J Luke, MD
Associate Professor and Director of the Cancer Immunotherapeutic Center
University of Pittsburgh Medical Center and Hillman Cancer Center
Pittsburgh, Pennsylvania

Advisory Committee: 7 Hills Pharma LLC, Actym Therapeutics, Alphamab Oncology, Array BioPharma Inc, BD, Benevir Biopharm Inc, Mavupharma, Tempest Therapeutics; Consulting Agreements: AbbVie Inc, Aduro Biotech, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Castle Biosciences Incorporated, CheckMate Pharmaceuticals, Compugen, EMD Serono Inc, IDEAYA Biosciences, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics Inc, Leap Therapeutics Inc, Merck, Mersana Therapeutics, NewLink Genetics Corporation, Novartis, RefleXion Medical, Spring Bank Pharmaceuticals, Tempest Therapeutics, Vividion; Contracted Research: AbbVie Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celldex Therapeutics, CheckMate Pharmaceuticals, Compugen, Corvus Pharmaceuticals, Delcath Systems Inc, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, FLX Bio Inc, Genentech, Immunocore, Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Novartis, Palleon Pharmaceuticals, Pharmacyclics LLC, an AbbVie Company, Tesaro, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology.

Jeffrey S Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Consulting Agreements: Altor Bioscience Corp, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Biond Biologics, Blueprint Medicines, Bristol-Myers Squibb Company, Celldex Therapeutics, CytomX Therapeutics, Genentech, GlaxoSmithKline, Incyte Corporation, Merck, Pfizer Inc, Protean LLC, Sellas Life Sciences, Takeda Oncology; Contracted Research: NextCure Inc; Ownership Interest: Altor Bioscience Corp, Biond Biologics, CytomX Therapeutics, Protean LLC; Patents: Biodesix Inc, Moffitt Cancer Center.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech, Merck and Novartis.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2019
Expiration date: July 2020